The American Association of Clinical Endocrinologists and American College of Endocrinology has updated their guidelines for management of dyslipidemia and prevention of atherosclerosis.

The guideline’s executive summary contains 87 recommendations. It provides guidance on screening, risk assessment, and treatment recommendations for a range of patients with various lipid disorders. It emphasizes the importance of treating low-density lipoprotein cholesterol in some individuals to lower goals more than previously recommended and support the measurement of coronary artery calcium scores and inflammatory markers to help stratify risk.

Special consideration is given to patients with diabetes, familial hypercholesterolemia, women, and pediatric patients with dyslipidemia. Both clinical and cost-effectiveness data are provided to support treatment decision-making.